Health Care : Current Reviews

Preoperative Etoricoxib reduces opioid use and improves clinical recovery after a total knee replacement

Euro Health Care and Fitness Summit

September 01-03, 2015 Valencia, Spain

Chia-Liang Ang

Singapore General Hospital, Singapore

Posters-Accepted Abstracts: Health Care: Current Reviews

Abstract:

Effective ways of reducing pain after a total knee replacement (TKR) without inducing excessive opioid-related side effects are important for the patientâ??s rehabilitation. In this double-blinded randomized controlled trial, we compared the effects of preoperative etoricoxib with placebo in reducing pain and improving range of motion of the knee. Patients were randomized into one of two groups: Etoricoxib 120 mg (33 patients) or an identical-appearing placebo (32 patients), taken at 24 hours and at 2 hours before a total knee arthroplasty. For both groups, postoperative analgesia consisted of patient-controlled analgesia (PCA) with intravenous morphine boluses, oral paracetamol and etoricoxib. The etoricoxib group had a significantly lower mean usage of PCA in the first 16 hours as compared to placebo (first 8 hours: 3.8 mg vs. 5.9mg, p=0.041; second 8 hours: 3.2 mg vs. 6.5mg, p=0.023). The etoricoxib group also demonstrated greater active range of motion of the knee at the third and fourth postoperative days (mean: 85° vs. 68°, p=0.018). Postoperative pain scores and drop in hemoglobin were similar between the groups. The pre-emptive administration of etoricoxib before a total knee arthroplasty resulted in reduced postoperative use of intravenous morphine and accelerated rehabilitation as compared to placebo.

Biography :

Email: med80199@yahoo.com